Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2009-02-02

Last Posted Date: 2014-11-21

Lead Sponsor: Janssen-Cilag G.m.b.H

Target Recruit Count: 401

Registration Number: NCT00833560

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Leukemia

Interventions: Drug: bortezomib
Drug: vorinostat

First Posted Date: 2009-01-08

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 16

Registration Number: NCT00818649

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Phase 2

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: bortezomib
Drug: Prednisone

First Posted Date: 2008-12-31

Last Posted Date: 2015-07-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00815919

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

PAD. ICORG 05-01, V11

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: Bortezomib
Drug: Doxorubicin
Drug: Dexamethasone

First Posted Date: 2008-12-25

Last Posted Date: 2014-12-31

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 53

Registration Number: NCT00814541

Locations: 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇮🇪
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, Ireland

and more 5 locations